Compare GIPR & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIPR | IMRN |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 12.0M |
| IPO Year | 2021 | N/A |
| Metric | GIPR | IMRN |
|---|---|---|
| Price | $0.81 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 63.6K | ★ 84.6K |
| Earning Date | 11-17-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,953,920.00 | $4,777,422.00 |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $0.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.63 |
| 52 Week Low | $0.63 | $0.68 |
| 52 Week High | $2.06 | $2.39 |
| Indicator | GIPR | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 46.68 |
| Support Level | $0.71 | $0.93 |
| Resistance Level | $0.88 | $1.05 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 75.47 | 40.56 |
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.